COMP <GO>
STOK vs ABBV // EV/EBITDA & P/E VALUATION
Stoke Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: STOK 2
— ABBV 8
■ METRIC PARITY
LAST: $26.35 (-0.23%) • MKT CAP: $1.70B
valuation
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STOK VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | STOK | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -6.10% | 29.00% | -35.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.64% | 3.47% | -0.83 | ABBV | /fcf-yield <GO> |
| Operating Margin | -11.20% | 24.60% | -35.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -3.70% | 6.90% | -10.60 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 8.60% | +171.40 | STOK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.79 | 5.33 | +9.46 | STOK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.3 | 65.1 | -12.79 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.70B | $513.86B | -$512.16B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | STOK REV | ABBV REV | STOK GROSS % | ABBV GROSS % | STOK FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $184.4M | $61.16B | — | 70.2% | $44.9M | $17.82B |
| FY 2024 | $36.6M | $56.33B | — | 70.0% | -$87.1M | $17.83B |
| FY 2023 | $8.8M | $54.32B | — | — | -$81.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STOK // BETA —
ABBV // BETA 1.15